The body hunters : testing new drugs on the world's poorest patients
Record details
- ISBN: 1565849124
- ISBN: 9781565849129
-
Physical Description:
print
xiii, 242 pages ; 22 cm - Publisher: New York : New Press : Distributed by W.W. Norton, 2006.
Content descriptions
Bibliography, etc. Note: | Includes bibliographical references (pages 179-232) and index. |
Formatted Contents Note: | 1. Clinical trials go global -- 2. The placebo control -- 3. Growing the pharma monolith -- 4. Uncaging the guinea pig -- 5. HIV and the second-rate solution -- 6. South Africa : drug trials and AIDS denialism -- 7. Outsourcing to India : the one billion body politic -- 8. Calibrating ethical codes -- 9. The emperor has no clothes : the vagaries of informed consent -- 10. Tipping the scales. |
Search for related items by subject
Available copies
- 1 of 1 copy available at Kirtland Community College.
Holds
- 0 current holds with 1 total copy.
Show Only Available Copies
Location | Call Number / Copy Notes | Barcode | Shelving Location | Status | Due Date |
---|---|---|---|---|---|
Kirtland Community College Library | RA 401 .D44 S53 2006 | 30775305494321 | General Collection | Available | - |
Electronic resources
The Body Hunters : Testings New Drugs on the World's Poorest Patients
Click an element below to view details:
Summary
The Body Hunters : Testings New Drugs on the World's Poorest Patients
Hailed by John le Carré as "an act of courage on the part of its author" and singled out for praise by the leading medical journals in the United States and the United Kingdom, The Body Hunters uncovers the real-life story behind le Carré's acclaimed novel The Constant Gardener and the feature film based on it. "A trenchant exposé . . . meticulously researched and packed with documentary evidence" ( Publishers Weekly ), Sonia Shah's riveting journalistic account shines a much-needed spotlight on a disturbing new global trend. Drawing on years of original research and reporting in Africa and Asia, Shah examines how the multinational pharmaceutical industry, in its quest to develop lucrative drugs, has begun exporting its clinical research trials to the developing world, where ethical oversight is minimal and desperate patients abound. As the New England Journal of Medicine notes, "it is critical that those engaged in drug development, clinical research and its oversight, research ethics, and policy know about these stories," which tell of an impossible choice being faced by many of the world's poorest patients--be experimented upon or die for lack of medicine.